GlassScriptPhysician profile
Yerie Yang
NPI 1073960498
$1,753.59
in general payments reported to CMS, 2019-2025
27 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.09 · 2023: $340 · 2024: $996 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.32 | 2023-2024 | Vraylar |
| Amgen INC. | $163.23 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $147.90 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $145.62 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $125.86 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Xeris Pharmaceuticals, INC. | $116.58 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $111.89 | 2024-2025 | |
| Astellas Pharma US INC | $77.46 | 2024-2025 | Veozah |
| Novo Nordisk INC | $60.47 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $56.83 | 2024 | Rexulti |
| Exact Sciences Corporation | $50.37 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $49.95 | 2024 | |
| Janssen Pharmaceuticals, INC | $41.40 | 2025 | Spravato |
| Shield Therapeutics INC | $41.34 | 2024 | |
| Dynavax Technologies Corporation | $35.08 | 2024 | Heplisav-B |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.25 | 2024-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $32.29 | 2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $29.09 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $27.62 | 2024 | Opsumit, Uptravi |
| Globus Medical, INC. | $21.75 | 2025 | Vyrsa V1 |
| Inspire Medical Systems, INC. | $21.65 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2024 | |
| Tonix Medicines, INC. | $19.00 | 2025 | Tonmya |
| Vivus LLC | $18.01 | 2023 | Qsymia |
| Amneal Pharmaceuticals LLC | $17.86 | 2025 | Crexont |
| Phathom Pharmaceuticals, INC. | $17.15 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $14.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yerie Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.